GlassScriptPhysician profile
Kenneth Spielvogel
NPI 1235104605
$1,904.16
in general payments reported to CMS, 2019-2025
34 companies · $34.27 in 2025
The $34.27 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $553 · 2021: $606 · 2022: $400 · 2023: $58.21 · 2024: $43.57 · 2025: $34.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.85 | 2019-2025 | Lo Loestrin Fe |
| Janssen Biotech, INC. | $158.92 | 2020-2022 | |
| Glaxosmithkline, LLC. | $142.11 | 2020-2022 | |
| Pulmonx Corporation | $126.76 | 2020-2022 | |
| Astellas Pharma US INC | $124.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $105.17 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.88 | 2021-2023 | |
| Pfizer INC. | $69.74 | 2020-2022 | |
| Grifols USA, LLC | $58.72 | 2020-2021 | |
| Allergan, INC. | $53.88 | 2019 | |
| Covidien LP | $53.34 | 2019-2020 | |
| Novo Nordisk INC | $40.42 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $38.42 | 2019-2021 | |
| Coopersurgical, INC. | $37.51 | 2021-2022 | |
| Exeltis, USA INC. | $37.16 | 2020-2024 | Slynd |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $36.84 | 2022-2023 | Aptima |
| Astrazeneca Pharmaceuticals LP | $30.68 | 2020-2021 | |
| Therapeuticsmd, INC. | $28.50 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.84 | 2020 | |
| Esperion Therapeutics, INC. | $26.81 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.63 | 2020 | |
| Sage Therapeutics, LLC | $22.42 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.07 | 2019 | |
| Mayne Pharma Commercial LLC | $19.82 | 2022 | |
| Amgen INC. | $19.72 | 2021 | |
| Evofem Biosciences, INC. | $19.62 | 2021 | |
| Boston Scientific Corporation | $19.11 | 2021 | |
| Olympus America INC. | $18.44 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.16 | 2021 | |
| Viiv Healthcare Company | $16.16 | 2025 | Apretude |
| Ethicon US, LLC | $15.96 | 2019 | |
| Si-Bone, INC. | $15.63 | 2019 | |
| Phadia US INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Spielvogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.